Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Human
Monoclonal
IgG1, lambda2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ELISA, Neutralization
Human
Monoclonal
IgG1, kappa
Iv0221
Serum, plasma, and other biological fluid samples
0.84 ng/mL
1.56 - 100 ng/mL
E. coli
P0DTC2 & P0DTC4 & P0DTC5
RBD [Arg319-Phe541] & E [Arg38-Val75] & M [Arg101-Gln222]
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Serum, plasma, and other biological fluid samples
3.5 pg/mL
12.5–800 pg/mL
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ELISA, Neutralization
Human
Monoclonal
IgG1, kappa
Iv0222
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Neutralization
Human
Monoclonal
IgG1, kappa
CC40.8
Middle East respiratory syndrome-related coronavirus (MERS-CoV)
ELISA, Neutralization
Human
Monoclonal
IgG1, kappa
m336
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Human
Monoclonal
IgG1-lambda
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Human
Monoclonal
IgG1
BD55-5514